Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer
Journal article published in 2019 by
Ilaria Alborelli 
,
Katharina Leonards ,
Sacha I. Rothschild,
Laura P. Leuenberger ,
Spasenija Savic Prince,
Kirsten D. Mertz ,
Severin Poechtrager,
Martin Buess,
Alfred Zippelius ,
Heinz Läubli,
Jasmin Haegele,
Markus Tolnay,
Lukas Bubendorf,
Luca Quagliata,
Philip Jermann
,
Katharina Leonards ,
Sacha I. Rothschild,
Laura P. Leuenberger ,
Spasenija Savic Prince,
Kirsten D. Mertz ,
Severin Poechtrager,
Martin Buess,
Alfred Zippelius ,
Heinz Läubli,
Jasmin Haegele,
Markus Tolnay,
Lukas Bubendorf,
Luca Quagliata,
Philip Jermann
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 